Lesokhin, Alexander M.

Publications

Sort by

Co-Author Network

selected publications

Accelerated single cell seeding in relapsed multiple myeloma. Nature communications. 2020 Academic Article GET IT
Times cited: 29
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020 Academic Article GET IT
Times cited: 5
Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies. 2019 GET IT
Times cited: 24
Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma. Cancer immunology research. 2019 Review GET IT
Times cited: 24
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition. Blood advances. 2019 Academic Article GET IT
Times cited: 37
Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma. Blood advances. 2019 Letter GET IT
Times cited: 8
Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample Database. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Academic Article GET IT
Times cited: 13
Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. Leukemia & lymphoma. 2018 Letter GET IT
Times cited: 14
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 26
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 132
Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma. Leukemia & lymphoma. 2017 Letter GET IT
Times cited: 7
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance. Leukemia & lymphoma. 2017 Letter GET IT
Times cited: 2
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017 Academic Article GET IT
Times cited: 133
Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Leukemia & lymphoma. 2017 Academic Article GET IT
Times cited: 41
Proteomic profiling in plasma cell disorders: a feasibility study. Leukemia & lymphoma. 2016 Letter GET IT
Times cited: 6
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency. Leukemia & lymphoma. 2016 Academic Article GET IT
Times cited: 8
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 703
Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. Clinical biochemistry. 2016 Academic Article GET IT
Times cited: 41
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 757
Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab. The Annals of pharmacotherapy. 2016 Review GET IT
Times cited: 20
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. European journal of cancer (Oxford, England : 1990). 2016 Review GET IT
Times cited: 287
Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. Blood. 2016 Letter GET IT
Times cited: 12
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. 2016 GET IT
Times cited: 217
Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine. 2016 Academic Article GET IT
Times cited: 106
Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation. Leukemia & lymphoma. 2016 Academic Article GET IT
Times cited: 3
Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study. Bone marrow transplantation. 2016 Academic Article GET IT
Times cited: 34
T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy. Cancer immunology research. 2015 Academic Article GET IT
Times cited: 126
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015 Academic Article GET IT
Times cited: 22
On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Science translational medicine. 2015 Review GET IT
Times cited: 123
Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nature reviews. Clinical oncology. 2015 Review GET IT
Times cited: 88
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. The New England journal of medicine. 2014 Academic Article GET IT
Times cited: 2747
Harnessing the immune system for cancer therapy. Current opinion in oncology. 2014 Review GET IT
Times cited: 18
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood. 2014 Academic Article GET IT
Times cited: 69
Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer immunology research. 2014 Academic Article GET IT
Times cited: 104
Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma. Methods in molecular biology (Clifton, N.J.). 2014 Academic Article GET IT
Times cited: 7
Nivolumab plus ipilimumab in advanced melanoma. The New England journal of medicine. 2013 Academic Article GET IT
Times cited: 3352
Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance. Leukemia. 2013 Letter GET IT
Times cited: 13
Myeloid-derived suppressor sells and the efficacy of CD8⁺ T-cell immunotherapy. Oncoimmunology. 2013 Academic Article GET IT
Times cited: 1584
Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center. Bone marrow transplantation. 2013 Academic Article GET IT
Times cited: 32
Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. The Journal of experimental medicine. 2012 Academic Article GET IT
Times cited: 110
Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation. Bone marrow transplantation. 2012 Academic Article GET IT
Times cited: 42
Immunologic correlates of the abscopal effect in a patient with melanoma. 2012 GET IT
Times cited: 1584
Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer research. 2011 Academic Article GET IT
Times cited: 270
Hiding the road signs that lead to tumor immunity. The Journal of experimental medicine. 2011 Review GET IT
Times cited: 12
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. Leukemia & lymphoma. 2011 Academic Article GET IT
Times cited: 15
Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood. 2010 Academic Article GET IT
Times cited: 96
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. The Journal of experimental medicine. 2009 Academic Article GET IT
Times cited: 177
Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. The Journal of experimental medicine. 2009 Academic Article GET IT
Times cited: 87
Inhibition of chemokine expression by adenovirus early region three (E3) genes. Journal of virology. 2002 Academic Article GET IT
Times cited: 30
Several levels of EGF receptor signaling during photoreceptor specification in wild-type, Ellipse, and null mutant Drosophila. Developmental biology. 1999 Academic Article GET IT
Times cited: 105

more ...

less ...

Background

education and training

M.D., Albert Einstein College of Medicine of Yeshiva University 2002
B.A., Queens College, City University of New York 1995

Contact

full name

Alexander M. Lesokhin

VIVO Weill Cornell Medical College

Alexander M. Lesokhin Associate Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name